Cochrane · systematic review · CD002913
Budesonide for maintenance of remission in Crohn's disease
Kuenzig, ME, Rezaie, A, Seow, CH, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 15.4%Low 2 · 15.4%Moderate 9 · 69.2%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Budesonide 6 mg versus placebo for maintenance of remission in Crohn's disease
Population: patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Continued remission at 3 months Budesonide 6 mg vs placebo | RR 1.25 [1, 1.58] | 6 studies · 540 participants | Low Downgraded: imprecision, inconsistency |
Continued remission at 6 months Budesonide 6 mg vs placebo | RR 1.15 [0.95, 1.39] | 5 studies · 420 participants | Moderate Downgraded: imprecision |
Continued remission at 12 months Budesonide 6 mg vs placebo | RR 1.13 [0.94, 1.35] | 5 studies · 420 participants | Moderate Downgraded: imprecision |
Budesonide 3 mg versus placebo for maintenance of remission in Crohn's disease
Population: patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Continued remission at 3 months Budesonide 3 mg vs placebo | RR 1.29 [1.01, 1.63] | 4 studies · 263 participants | Moderate Downgraded: imprecision |
Continued remission at 6 months Budesonide 3 mg vs placebo | RR 1.12 [0.83, 1.51] | 3 studies · 180 participants | Moderate Downgraded: imprecision |
Continued remission at 12 months Budesonide 3 mg vs placebo | RR 1.08 [0.87, 1.34] | 5 studies · 442 participants | Moderate Downgraded: imprecision |
Budesonide 6 mg versus budesonide 3 mg for maintenance of remission in Crohn's disease
Population: patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Continued remission at 3 months Budesonide 6 mg vs budesonide 3 mg | RR 1.07 [0.85, 1.34] | 3 studies · 180 participants | Moderate Downgraded: imprecision |
Continued remission at 6 months Budesonide 6 mg vs budesonide 3 mg | RR 1.12 [0.85, 1.47] | 3 studies · 180 participants | Moderate Downgraded: imprecision |
Continued remission at 12 months Budesonide 6 mg vs budesonide 3 mg | RR 1.18 [0.85, 1.65] | 3 studies · 180 participants | Moderate Downgraded: imprecision |
Budesonide 9 mg versus budesonide 6 mg for maintenance of remission in Crohn's disease
Population: patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Continued remission at 12 months Budesonide 9 mg vs budesonide 6 mg | RR 1.07 [0.91, 1.26] | 1 study · 157 participants | Moderate Downgraded: imprecision |
Budesonide 9 mg versus prednisolone 40 mg for maintenance of remission in Crohn's disease
Population: patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Continued remission at 12 months Budesonide 9 mg vs prednisolone 40 mg | RR 0.79 [0.55, 1.13] | 1 study · 90 participants | Low Downgraded: risk of bias, imprecision |
Budesonide 6 mg versus mesalamine 3 g for maintenance of remission in Crohn's disease
Population: patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Continued remission at 12 months Budesonide 6 mg vs mesalamine 3 g | RR 2.51 [1.03, 6.12] | 1 study · 57 participants | Very low Downgraded: risk of bias, imprecision |
Budesonide 6‐9 mg versus azathioprine 2‐2.5 mg/kg for maintenance of remission in Crohn's disease
Population: patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Continued remission at 12 months Budesonide 6‐9 mg vs azathioprine 2‐2.5 mg/kg | RR 0.81 [0.61, 1.08] | 1 study · 77 participants | Very low Downgraded: risk of bias, imprecision |